NYSE: CRLCharles River Laboratories International Inc Stock
$163.22+0.42 (+0.26%)
Updated Aug 28, 2025
CRL Price
$163.22
Fair Value Price
N/A
Market Cap
$8.03B
52 Week Low
$91.86
52 Week High
$230.02
P/E
-126.53x
P/B
2.4x
P/S
1.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.03B
Earnings
-$67.04M
Gross Margin
32.5%
Operating Margin
2.38%
Profit Margin
-1.7%
Debt to Equity
1.24
Operating Cash Flow
$787M
Beta
1.23
Next Earnings
Oct 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CRL Overview
Charles River Laboratories International, Inc. offers a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services to the Pharmaceutical, Medical Device, and Biotechnology sectors. Charles River was founded in 1947 and is headquartered in Wilmington, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRL's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
CRL
Ranked#3 of 41
Ranked#3 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.88 | A | |
| $16.20 | A | |
| $647.03 | B |
Be the first to know about important CRL news, forecast changes, insider trades & much more!
CRL News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRL is good value based on its book value relative to its share price (2.4x), compared to the US Diagnostics & Research industry average (3.86x)
P/B vs Industry Valuation
CRL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRL due diligence checks available for Premium users.
Valuation
CRL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-126.53x
Industry
22.33x
Market
35.78x
CRL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.4x
Industry
3.86x
CRL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRL's financial health
Profit margin
Revenue
$1.0B
Net Income
$52.3M
Profit Margin
5.1%
CRL's Earnings (EBIT) of $96.05M... subscribe to Premium to read more.
Interest Coverage Financials
CRL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.6B
Liabilities
$4.2B
Debt to equity
1.24
CRL's short-term assets ($1.47B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRL's long-term liabilities ($3.08B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$204.6M
Investing
-$37.3M
Financing
-$226.9M
CRL's operating cash flow ($787.45M)... subscribe to Premium to read more.
Debt Coverage Financials
CRL vs Diagnostic & Research Stocks
Charles River Laboratories International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.